Guizhou Xinbang Pharmaceutical Co Ltd (002390) - Net Assets

Latest as of September 2025: CN¥6.97 Billion CNY ≈ $1.02 Billion USD

Based on the latest financial reports, Guizhou Xinbang Pharmaceutical Co Ltd (002390) has net assets worth CN¥6.97 Billion CNY (≈ $1.02 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.59 Billion ≈ $1.26 Billion USD) and total liabilities (CN¥1.62 Billion ≈ $236.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see 002390 company net worth.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥6.97 Billion
% of Total Assets	81.17%
Annual Growth Rate	24.09%
5-Year Change	35.82%
10-Year Change	163.02%
Growth Volatility	73.3

Guizhou Xinbang Pharmaceutical Co Ltd - Net Assets Trend (2006–2024)

This chart illustrates how Guizhou Xinbang Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data.

Annual Net Assets for Guizhou Xinbang Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual net assets of Guizhou Xinbang Pharmaceutical Co Ltd from 2006 to 2024. See Guizhou Xinbang Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.

Year	Net Assets	Change
2024-12-31	CN¥7.02 Billion ≈ $1.03 Billion	-1.71%
2023-12-31	CN¥7.14 Billion ≈ $1.05 Billion	+1.09%
2022-12-31	CN¥7.07 Billion ≈ $1.03 Billion	+3.46%
2021-12-31	CN¥6.83 Billion ≈ $999.22 Million	+32.12%
2020-12-31	CN¥5.17 Billion ≈ $756.31 Million	+2.38%
2019-12-31	CN¥5.05 Billion ≈ $738.73 Million	-2.33%
2018-12-31	CN¥5.17 Billion ≈ $756.32 Million	-23.53%
2017-12-31	CN¥6.76 Billion ≈ $989.00 Million	+4.22%
2016-12-31	CN¥6.49 Billion ≈ $948.96 Million	+142.97%
2015-12-31	CN¥2.67 Billion ≈ $390.56 Million	+8.59%
2014-12-31	CN¥2.46 Billion ≈ $359.67 Million	+137.27%
2013-12-31	CN¥1.04 Billion ≈ $151.59 Million	+1.30%
2012-12-31	CN¥1.02 Billion ≈ $149.64 Million	+4.40%
2011-12-31	CN¥979.53 Million ≈ $143.34 Million	+2.07%
2010-12-31	CN¥959.70 Million ≈ $140.43 Million	+279.58%
2009-12-31	CN¥252.83 Million ≈ $37.00 Million	+21.73%
2008-12-31	CN¥207.69 Million ≈ $30.39 Million	+19.31%
2007-12-31	CN¥174.08 Million ≈ $25.47 Million	+20.75%
2006-12-31	CN¥144.17 Million ≈ $21.10 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Guizhou Xinbang Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 1182.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥456.75 Million	6.81%
Common Stock	CN¥1.94 Billion	28.97%
Other Components	CN¥4.31 Billion	64.22%
Total Equity	CN¥6.71 Billion	100.00%

Guizhou Xinbang Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Guizhou Xinbang Pharmaceutical Co Ltd ranked by their market capitalization.

Company	Market Cap
Scandinavian Tobacco Group A/S CO:STG	$864.90 Million
Guangdong Lvtong New Energy Electric Vehicle Technology Co. Ltd. Cl A SHE:301322	$865.04 Million
SG Fleet Group Ltd AU:SGF	$865.28 Million
Niutech Environment Technology Corp SHG:688309	$865.38 Million
PWR Holdings Ltd AU:PWH	$864.63 Million
Shenzhen Feima International Supply Chain Co Ltd SHE:002210	$864.52 Million
DBV Technologies S.A. PA:DBV	$864.20 Million
S.J.S. Enterprises Limited NSE:SJS	$864.18 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guizhou Xinbang Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 6,852,401,000 to 6,710,056,000, a change of -142,345,000 (-2.1%).
Net income of 101,381,627 contributed positively to equity growth.
Dividend payments of 192,290,000 reduced retained earnings.
Share repurchases of 78,985,852 reduced equity.
Other comprehensive income decreased equity by 201,046,000.
Other factors increased equity by 228,595,225.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥101.38 Million	+1.51%
Dividends Paid	CN¥192.29 Million	-2.87%
Share Repurchases	CN¥78.99 Million	-1.18%
Other Comprehensive Income	CN¥-201.05 Million	-3.0%
Other Changes	CN¥228.60 Million	+3.41%
Total Change	CN¥-	-2.08%

Book Value vs Market Value Analysis

This analysis compares Guizhou Xinbang Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.86x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 13.76x to 0.86x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-12-31	CN¥0.22	CN¥3.04	x
2007-12-31	CN¥0.27	CN¥3.04	x
2008-12-31	CN¥0.32	CN¥3.04	x
2009-12-31	CN¥0.39	CN¥3.04	x
2010-12-31	CN¥1.22	CN¥3.04	x
2011-12-31	CN¥1.15	CN¥3.04	x
2012-12-31	CN¥1.19	CN¥3.04	x
2013-12-31	CN¥1.23	CN¥3.04	x
2014-12-31	CN¥2.15	CN¥3.04	x
2015-12-31	CN¥2.04	CN¥3.04	x
2016-12-31	CN¥3.87	CN¥3.04	x
2017-12-31	CN¥3.94	CN¥3.04	x
2018-12-31	CN¥3.06	CN¥3.04	x
2019-12-31	CN¥3.03	CN¥3.04	x
2020-12-31	CN¥3.11	CN¥3.04	x
2021-12-31	CN¥3.64	CN¥3.04	x
2022-12-31	CN¥3.64	CN¥3.04	x
2023-12-31	CN¥3.58	CN¥3.04	x
2024-12-31	CN¥3.54	CN¥3.04	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guizhou Xinbang Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 1.51%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 1.68%
• Asset Turnover: 0.67x
• Equity Multiplier: 1.35x
Recent ROE (1.51%) is below the historical average (5.19%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	12.22%	10.07%	0.46x	2.66x	CN¥3.17 Million
2007	17.32%	13.74%	0.56x	2.27x	CN¥12.65 Million
2008	16.28%	12.23%	0.62x	2.14x	CN¥12.97 Million
2009	18.44%	13.87%	0.72x	1.86x	CN¥21.37 Million
2010	3.93%	11.85%	0.28x	1.17x	CN¥-58.26 Million
2011	4.70%	12.73%	0.29x	1.27x	CN¥-51.95 Million
2012	4.70%	10.69%	0.34x	1.31x	CN¥-53.94 Million
2013	3.89%	7.07%	0.38x	1.44x	CN¥-63.25 Million
2014	6.04%	5.85%	0.47x	2.18x	CN¥-94.92 Million
2015	6.86%	4.17%	0.64x	2.56x	CN¥-79.81 Million
2016	3.87%	4.77%	0.48x	1.70x	CN¥-389.19 Million
2017	4.83%	5.32%	0.50x	1.81x	CN¥-342.15 Million
2018	-26.10%	-19.70%	0.61x	2.19x	CN¥-1.79 Billion
2019	4.89%	3.55%	0.64x	2.15x	CN¥-247.41 Million
2020	3.53%	2.97%	0.61x	1.96x	CN¥-318.31 Million
2021	4.12%	4.22%	0.67x	1.45x	CN¥-389.11 Million
2022	3.30%	3.53%	0.65x	1.44x	CN¥-456.47 Million
2023	4.19%	4.45%	0.70x	1.35x	CN¥-398.01 Million
2024	1.51%	1.68%	0.67x	1.35x	CN¥-569.62 Million

Industry Comparison

This section compares Guizhou Xinbang Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $3,352,842,306
Average return on equity (ROE) among peers: 9.09%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guizhou Xinbang Pharmaceutical Co Ltd (002390)	CN¥6.97 Billion	12.22%	0.23x	$864.72 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$1.06 Billion	5.59%	4.55x	$623.73 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$775.01 Million	2.45%	0.87x	$412.75 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$4.56 Billion
Livzon Pharmaceutical Group Inc (000513)	$14.91 Billion	13.83%	0.64x	$2.52 Billion
Wedge Industrial Co Ltd (000534)	$0.00	0.00%	0.00x	$2.02 Billion
Yunnan Baiyao Group Co Ltd (000538)	$410.41 Million	8.16%	0.86x	$12.88 Billion
Hainan Haiyao Co Ltd (000566)	$265.38 Million	9.41%	0.86x	$918.85 Million
Tus Pharmaceutical Group Co Ltd (000590)	$350.83 Million	20.56%	0.72x	$317.13 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.71 Billion	7.43%	1.93x	$1.05 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$1.18 Billion	2.75%	0.43x	$3.14 Billion

About Guizhou Xinbang Pharmaceutical Co Ltd

SHE:002390 China Drug Manufacturers - Specialty & Generic

Market Cap

$864.72 Million

CN¥5.91 Billion CNY

Market Cap Rank

#9588 Global

#2419 in China

Share Price

CN¥3.04

Change (1 day)

-3.80%

52-Week Range

CN¥2.60 - CN¥4.15

All Time High

CN¥14.40